1156 related articles for article (PubMed ID: 18974200)
1. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
3. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
4. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.
Patel NS; Mathura VS; Bachmeier C; Beaulieu-Abdelahad D; Laporte V; Weeks O; Mullan M; Paris D
J Neurochem; 2010 Jan; 112(1):66-76. PubMed ID: 19818105
[TBL] [Abstract][Full Text] [Related]
10. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
Nishi J; Minamino T; Miyauchi H; Nojima A; Tateno K; Okada S; Orimo M; Moriya J; Fong GH; Sunagawa K; Shibuya M; Komuro I
Circ Res; 2008 Aug; 103(3):261-8. PubMed ID: 18583712
[TBL] [Abstract][Full Text] [Related]
12. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
14. Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice.
Huh JE; Baek YH; Lee MH; Choi DY; Park DS; Lee JD
Cancer Lett; 2010 Jun; 292(1):98-110. PubMed ID: 20188461
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
16. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
17. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
20. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
